Preclinical Pharmacokinetic (PK) Study Execution

The contract involves the execution of preclinical pharmacokinetic studies in mice to evaluate the absorption, distribution, metabolism, and excretion of three lead compounds following both intravenous and oral administration. Blood samples will be collected at ten distinct time points across a 24-hour period to generate detailed concentration-time profiles for each compound, enabling the calculation of key pharmacokinetic parameters such as bioavailability, clearance, and half-life. The work is to be performed under a subcontract arrangement with the National Institutes of Health, operating under the Department of Health and Human Services, and is classified under NAICS code 541940 for other scientific and technical consulting services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and the studies are expected to be conducted at an unspecified location designated by the contracting entity. The scope requires strict adherence to standardized protocols for animal handling, sample processing, and data collection to ensure regulatory compliance and scientific rigor.